139 related articles for article (PubMed ID: 37269679)
1. Combined immune and DDR pathway classifier: A novel pathway-based classification aimed at tailoring personalized therapies for acute myeloid leukemia patients.
Huang Y; Zhang Y; Zhou Q; Teng Y; Sui M; Zhang F
Comput Biol Med; 2023 Aug; 162():107093. PubMed ID: 37269679
[TBL] [Abstract][Full Text] [Related]
2. DNA Damage Response-Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children's Oncology Group Study.
Hubner SE; de Camargo Magalhães ES; Hoff FW; Brown BD; Qiu Y; Horton TM; Kornblau SM
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982970
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia.
Park S; Kim YJ; Huh HJ; Chung HS; Lee M; Park YM; Mun YC; Seong CM; Huh J
Hematology; 2021 Dec; 26(1):904-913. PubMed ID: 34789078
[TBL] [Abstract][Full Text] [Related]
4. Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia.
Rosen DB; Putta S; Covey T; Huang YW; Nolan GP; Cesano A; Minden MD; Fantl WJ
PLoS One; 2010 Aug; 5(8):e12405. PubMed ID: 20811632
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of DNA damage repair in squamous cell carcinoma subtypes.
Qin F; Sun Y; Deng K; Qin J; Xu Z; Wei J; Yuan L; Zheng T; Li S
Life Sci; 2021 Aug; 278():119559. PubMed ID: 33932441
[TBL] [Abstract][Full Text] [Related]
6. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
7. DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.
Esposito MT; So CW
Chromosoma; 2014 Dec; 123(6):545-61. PubMed ID: 25112726
[TBL] [Abstract][Full Text] [Related]
8. A transient receptor potential channel-related model based on machine learning for evaluating tumor microenvironment and immunotherapeutic strategies in acute myeloid leukemia.
Hua J; Ding T; Shao Y
Front Immunol; 2022; 13():1040661. PubMed ID: 36591215
[TBL] [Abstract][Full Text] [Related]
9. KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition.
Boila LD; Ghosh S; Bandyopadhyay SK; Jin L; Murison A; Zeng AGX; Shaikh W; Bhowmik S; Muddineni SSNA; Biswas M; Sinha S; Chatterjee SS; Mbong N; Gan OI; Bose A; Chakraborty S; Arruda A; Kennedy JA; Mitchell A; Lechman ER; Banerjee D; Milyavsky M; Minden MD; Dick JE; Sengupta A
Leukemia; 2023 Apr; 37(4):751-764. PubMed ID: 36720973
[TBL] [Abstract][Full Text] [Related]
10. Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.
Zhou C; Lin A; Cao M; Ding W; Mou W; Guo N; Chen Z; Zhang J; Luo P
Front Immunol; 2021; 12():634741. PubMed ID: 34220801
[TBL] [Abstract][Full Text] [Related]
11. Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer.
Lou S; Wang Y; Zhang J; Yin X; Zhang Y; Wang Y; Xue Y
Front Immunol; 2021; 12():806324. PubMed ID: 35082793
[TBL] [Abstract][Full Text] [Related]
12. Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia.
Mumme HL; Raikar SS; Bhasin SS; Thomas BE; Lawrence T; Weinzierl EP; Pang Y; DeRyckere D; Gawad C; Wechsler DS; Porter CC; Castellino SM; Graham DK; Bhasin M
Genome Med; 2023 Oct; 15(1):83. PubMed ID: 37845689
[TBL] [Abstract][Full Text] [Related]
13. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment.
Lee C; Lee S; Park E; Hong J; Shin DY; Byun JM; Yun H; Koh Y; Yoon SS
Genome Med; 2022 Sep; 14(1):111. PubMed ID: 36171613
[TBL] [Abstract][Full Text] [Related]
15. Characterization of DNA Damage Repair Related Signature and Molecular Feature in Low-Grade Gliomas to Aid Chemotherapy and Drug Discovery.
Yin X; Li M; He Z
Front Biosci (Landmark Ed); 2023 Oct; 28(10):234. PubMed ID: 37919061
[TBL] [Abstract][Full Text] [Related]
16. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
Wang F
Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
[TBL] [Abstract][Full Text] [Related]
17. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
Front Immunol; 2021; 12():676922. PubMed ID: 34335575
[TBL] [Abstract][Full Text] [Related]
18. Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias.
Popp HD; Naumann N; Brendel S; Henzler T; Weiss C; Hofmann WK; Fabarius A
Leuk Res; 2017 Jun; 57():112-118. PubMed ID: 28359030
[TBL] [Abstract][Full Text] [Related]
19. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.
Boehrer S; Adès L; Tajeddine N; Hofmann WK; Kriener S; Bug G; Ottmann OG; Ruthardt M; Galluzzi L; Fouassier C; Tailler M; Olaussen KA; Gardin C; Eclache V; de Botton S; Thepot S; Fenaux P; Kroemer G
Oncogene; 2009 Jun; 28(22):2205-18. PubMed ID: 19398952
[TBL] [Abstract][Full Text] [Related]
20. Multi-omics analyses unravel DNA damage repair-related clusters in breast cancer with experimental validation.
Liu P; Deng X; Zhou H; Xie J; Kong Y; Zou Y; Yang A; Li X
Front Immunol; 2023; 14():1297180. PubMed ID: 38022619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
